Biotechnology Stem-Cell Regulation In Russia.

1. Introduction

Stem-cell regulation in Russia is governed by a combination of constitutional principles, federal legislation, healthcare regulations, biomedical research rules, pharmaceutical requirements, and human-subject protection standards.

Stem-cell biotechnology has significant applications in:

Regenerative medicine and tissue engineering.

Bone marrow and hematopoietic stem-cell transplantation.

Treatment of blood disorders and certain cancers.

Cell-based therapies for degenerative diseases.

Embryonic stem-cell research.

Induced pluripotent stem-cell (iPSC) technology.

Personalized medicine and genetic engineering.

Russia does not regulate every type of stem-cell activity through one comprehensive, standalone stem-cell statute. Instead, the legal framework distinguishes between biomedical cell products, medical treatment, scientific research, transplantation, and pharmaceutical products.

An important distinction is that the use of a stem-cell product in an experimental study is not automatically equivalent to authorization for routine clinical treatment.

2. Principal legislation governing stem-cell research

A. Federal Law No. 180-FZ of 23 June 2016 – On Biomedical Cell Products

This is the central legislation governing the commercial and clinical use of human cell-based products in Russia.

It regulates:

Development of biomedical cell products.

Preclinical investigations.

Clinical trials.

Scientific and ethical examination.

State registration.

Manufacturing and quality control.

Distribution and clinical application.

Transportation and storage.

Biological-material donation.

Post-market safety monitoring.

Articles 5–7 address development, preclinical research and product specifications. Articles 8–25 establish the registration and examination framework. Articles 28–32 govern clinical investigations and patient protection. Articles 33–38 address donors, production and handling, while Articles 39–48 deal with clinical application, safety monitoring, regulatory enforcement and compensation for injury.

Consultant Plus+1

 

Important legal principle: A biomedical cell product generally cannot be manufactured, marketed or clinically applied without the required regulatory authorization and registration, subject to statutory exceptions.

B. Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection of Citizens in the Russian Federation

This legislation establishes the general legal framework for medical treatment and healthcare.

Its relevance to stem-cell biotechnology includes:

Patient rights and informed consent.

Medical confidentiality.

Medical professional responsibilities.

Healthcare quality and safety.

Medical intervention standards.

Liability for improper medical treatment.

It complements Federal Law No. 180-FZ by regulating the healthcare relationship between the patient, medical institution and healthcare professional.

C. Federal Law No. 99-FZ of 4 May 2011 – On Licensing of Certain Types of Activities

This law establishes licensing requirements for regulated activities.

Biomedical cell-product manufacturing requires the appropriate production licence. Government Resolution No. 1184 of 3 October 2018 establishes specific licensing requirements for such manufacturing activities.

CIS Legislation+1

 

D. Ministry of Health Order No. 512n of 8 August 2018

This order establishes good-practice rules for handling biomedical cell products.

It addresses:

Personnel qualifications.

Production conditions.

Quality assurance.

Contamination prevention.

Documentation and traceability.

Storage and handling procedures.

These requirements are particularly important for laboratories producing autologous and allogeneic stem-cell products.

ealegislation.com+1

 

3. Regulatory authorities

Several Russian institutions have responsibilities relevant to stem-cell biotechnology.

AuthorityMain responsibility
Ministry of HealthHealthcare policy and regulatory authorization
RoszdravnadzorRegulatory supervision and licensing
Federal Medical-Biological Agency (FMBA)Medical-biological research and related healthcare functions
Ethics committeesEthical assessment of biomedical research
Authorized expert institutionsScientific, safety and quality assessment

The regulatory framework requires scientific evaluation as well as ethical assessment before relevant biomedical cell products can receive authorization.

consultant.ru+1

 

4. Legal classification of stem cells

The regulatory treatment depends on the type of cell, its origin, its intended purpose and how it is processed.

Stem-cell categoryPrincipal legal considerations
Embryonic stem cellsEmbryo-related ethical and legal restrictions
Adult stem cellsDonor consent, biological-material handling and clinical safety
Hematopoietic stem cellsTransplantation and blood-related legislation
Mesenchymal stem cellsBiomedical cell-product regulation where applicable
Induced pluripotent stem cellsResearch, genetic and cell-product requirements
Genetically modified stem cellsAdditional genetic-safety and biomedical regulatory issues

Important distinction: Federal Law No. 180-FZ expressly excludes certain activities from its scope, including human organs and tissues donated for transplantation, reproductive gametes used in assisted reproductive technologies, and cells and tissues handled for scientific or educational purposes. Therefore, not every stem-cell experiment or transplantation is automatically governed by the same registration procedure.

CIS Legislation+1

 

5. Donor consent and protection of biological material

Donor protection is a fundamental element of Russian stem-cell regulation.

Articles 33 and 34 of Federal Law No. 180-FZ regulate the collection of biological material and the rights and obligations of donors.

The legal framework addresses:

Voluntary donation of biological material.

Consent to collection and intended use.

Information about the purpose of biological-material collection.

Protection of donor interests.

Handling and storage of donated material.

Rights of parents and legal representatives where applicable.

Protection against unauthorized use of biological material.

The law distinguishes between:

Autologous stem-cell products: Cells obtained from an individual and intended for treatment of that same individual.

Allogeneic stem-cell products: Cells obtained from one individual for application to another individual.

Combined products: Products involving cell lines obtained from multiple individuals.

This classification is important because donor consent, traceability, compatibility and product-safety requirements can differ according to the type of product.

sudact.ru+1

 

6. Embryonic stem-cell research and ethical restrictions

Embryonic stem-cell research raises particular ethical and legal questions because it involves human embryos and reproductive biological material.

Relevant considerations include:

Protection of human dignity.

Voluntary consent concerning biological material.

Medical confidentiality.

Protection of reproductive rights.

Ethical review of scientific research.

Prevention of unauthorized commercial exploitation.

Compliance with applicable restrictions on embryo-related research.

Russian legislation does not treat embryonic stem-cell research as automatically equivalent to ordinary adult stem-cell research.

Federal Law No. 180-FZ excludes certain reproductive and scientific activities from its scope. Other legislation, including Federal Law No. 323-FZ and Federal Law No. 418-FZ of 20 December 2006 concerning the use of human embryos for biomedical research, must be considered where relevant.

A researcher must therefore determine whether the activity concerns an embryo, reproductive gametes, isolated cells or a biomedical cell product before deciding which legal authorization is required.

7. Clinical trials and medical authorization

Russia requires scientific and ethical evaluation before biomedical cell products can be introduced into clinical use under the applicable regulatory framework.

Under Articles 28–32 of Federal Law No. 180-FZ, clinical investigations involve:

An approved research protocol.

Scientific assessment.

Ethical assessment.

Appropriate clinical facilities.

Qualified medical professionals.

Patient information and informed consent.

Monitoring of adverse reactions.

Protection of research participants.

Article 31 specifically addresses the rights of patients participating in clinical investigations.

Article 32 provides for compulsory insurance of the life and health of patients participating in such investigations.

Legal significance: A patient participating in a clinical trial must receive appropriate information about the research, its objectives, possible risks and the nature of the investigational cell product.

consultant.ru+1

 

8. Special rules for individualized stem-cell products introduced in 2024

An important development occurred in 2024.

Federal Law No. 466-FZ of 4 August 2023 introduced Article 32.1 into Federal Law No. 180-FZ, creating a special framework for certain biomedical cell products manufactured directly within the medical organization for an individual patient.

The framework became operational through Government Resolution No. 384 of 28 March 2024.

This pathway is particularly relevant to personalized regenerative medicine.

It allows qualifying products to be considered under an individual medical prescription rather than simply treating them as ordinary mass-produced cell products.

Government Resolution No. 385 of 28 March 2024 establishes the associated rules for granting, confirming and cancelling authorization for production and application of these individualized products.

regmed.ru+1

 

The framework requires, among other things:

An appropriate medical organization.

Expert assessment of the proposed product.

An ethics committee conclusion.

Suitable production arrangements.

Relevant manufacturing and medical licences.

Appropriate emergency and intensive-care facilities.

Safety monitoring and reporting.

The authorization may be refused where the expert assessment finds that production and application are not justified or where the necessary licensing and institutional requirements are not satisfied.

Legal importance: The 2024 framework recognizes a special regulatory route for individualized cell-based treatment, but it does not create unrestricted permission for private stem-cell clinics to offer unapproved therapies.

9. Manufacturing, storage and quality control

Stem-cell manufacturing creates risks that are different from those associated with conventional medicines.

Examples include:

Microbial contamination.

Cross-contamination between cell lines.

Genetic instability.

Loss of cellular identity.

Inconsistent cell viability.

Improper cryopreservation.

Incorrect donor identification.

Inadequate product traceability.

Federal Law No. 180-FZ and Ministry of Health Order No. 512n establish requirements relevant to the quality and safe handling of biomedical cell products.

Government Resolution No. 1184 of 3 October 2018 regulates licensing of manufacturing activities.

cis-legislation.com+1

 

Manufacturers must establish appropriate systems for:

Quality assurance.

Standard operating procedures.

Personnel training.

Equipment maintenance.

Environmental monitoring.

Documentation.

Product identification.

Storage and transportation.

Prevention of contamination.

Failure to satisfy these requirements can lead to regulatory enforcement and interruption of manufacturing activities.

10. Patient safety, adverse reactions and compensation

Russian law recognizes that cell-based treatment may create serious medical risks.

Under Article 41 of Federal Law No. 180-FZ, safety monitoring is required for biomedical cell products.

Article 42 allows suspension of a product's application where information indicates serious safety concerns, including unexpected adverse reactions or risks that may threaten human life or health.

Consultant Plus+1

 

Article 48 establishes an important compensation framework.

SituationPotentially responsible party
Harm caused by a defective biomedical cell productManufacturer
Harm caused by inaccurate product instructionsManufacturer
Harm caused by use contrary to instructionsMedical organization
Harm caused by negligent medical treatmentResponsible medical organization or professional, according to applicable law

Compensation depends on establishing the relevant statutory conditions and causal connection.

This framework is important because stem-cell injuries can involve delayed complications, abnormal cell growth, immune reactions and other unexpected medical consequences.

old.volgmed.ru+1

 

11. Important Russian court cases and judicial decisions

Russian judicial decisions specifically interpreting Federal Law No. 180-FZ are comparatively limited. However, several legal disputes and statutory provisions provide useful guidance for understanding the regulation of cellular medicine.

Case 1. Public Joint-Stock Company Institute of Human Stem Cells v. Roszdravnadzor

Relevant reported judicial decision

Court: Supreme Court of the Russian Federation.

Date: 13 June 2017.

Case number: A40-58903/2016.

Supreme Court reference: No. 305-KG17-6103.

Facts

The Institute of Human Stem Cells held a medical licence issued on 14 March 2012. The licence covered high-technology medical assistance involving cellular technologies.

Roszdravnadzor inspected the organization and issued an enforcement order on 23 December 2015.

The authority required the organization to bring its licence into conformity with the applicable medical licensing requirements.

The Institute challenged the enforcement order.

Judicial proceedings

Moscow Arbitration Court, 22 July 2016: Rejected the Institute's claim.

Ninth Arbitration Court of Appeal, 31 October 2016: Reversed the first-instance judgment and granted the Institute's claim.

Moscow District Arbitration Court, 21 February 2017: Reversed the appellate judgment and restored the first-instance judgment.

Supreme Court, 13 June 2017: Refused to transfer the Institute's complaint for consideration by the Judicial Collegium for Economic Disputes.

sudact.ru+2

Legal principle

The dispute concerned the need to bring an existing medical licence into conformity with updated licensing requirements.

The courts examined the relationship between earlier licences, the revised list of medical services and the statutory licensing framework.

Importance for stem-cell regulation

The decision demonstrates that conducting advanced cellular medical procedures does not exempt an institution from ordinary medical licensing requirements.

It also illustrates the importance of distinguishing between authorization to provide medical services and authorization to manufacture biomedical cell products.

Important qualification: This dispute concerned the regulatory framework before the implementation of Federal Law No. 180-FZ. It is relevant historical case law, not a judicial interpretation of the current biomedical cell-product registration system.

Case 2. Institute of Human Stem Cells licensing dispute – appellate judgment of 31 October 2016

Court: Ninth Arbitration Court of Appeal.

Case number: A40-58903/2016.

Date: 31 October 2016.

This is the appellate stage of the same litigation described above, not a separate independent case.

Legal issue

Whether Roszdravnadzor's enforcement order requiring the Institute to amend its medical licence was lawful.

Importance

The appellate court initially found in favour of the Institute. However, that judgment was subsequently reversed by the Moscow District Arbitration Court.

Consequently, the appellate ruling should not be presented as the final outcome of the litigation.

sudact.ru+1

 

Case 3. Regulatory supervision under Government Resolution No. 1062 of 30 June 2021

This is a regulatory framework rather than an individual judicial case.

The resolution governs federal state supervision of the circulation of biomedical cell products.

Roszdravnadzor is responsible for relevant regulatory supervision.

The framework is significant for disputes involving:

Manufacturing compliance.

Product quality.

Regulatory inspections.

Improper handling of cell products.

Safety-monitoring failures.

Suspension of product application.

The official regulatory authority identifies the resolution and its updated regulatory materials.

roszdravnadzor.gov.ru+1

 

Legal principle: Biomedical cell-product regulation is subject to continuing state supervision, not merely a one-time authorization process.

Case 4. Regulatory enforcement and destruction of defective biomedical cell products

This is a statutory enforcement framework, rather than a separately identified stem-cell court judgment.

The administrative rules governing Roszdravnadzor inspections provide for:

Orders requiring violations to be corrected.

Referral of suspected criminal violations to law-enforcement authorities.

Withdrawal and destruction of defective or falsified biomedical cell products.

Court proceedings where an organization disputes or fails to comply with an applicable destruction decision.

sudact.ru+1

Legal significance

This framework protects patients against unsafe or falsely represented cell-based products and provides a basis for judicial review of regulatory enforcement.

12. Criminal and administrative liability

Violations of Russian stem-cell regulations can result in administrative, civil and, in serious cases, criminal liability.

Administrative liability

Potential violations include:

Manufacturing without the required licence.

Breaching mandatory production standards.

Violating medical licensing requirements.

Distributing defective biomedical cell products.

Providing misleading information about medical treatments.

Breaching applicable patient-protection requirements.

Depending on the conduct, relevant provisions of the Russian Code of Administrative Offences may apply, including Article 14.1 (unlicensed entrepreneurial activity), Article 14.4 (sale of goods or provision of services of inadequate quality) and Article 19.20 (unlicensed activity not connected with profit-making).

Criminal liability

Depending on the facts, relevant provisions of the Russian Criminal Code may include:

Article 109 – Causing death by negligence.

Article 118 – Causing serious harm to health by negligence.

Article 238 – Provision of services that do not meet safety requirements.

Article 235 – Illegal practice of private medical or pharmaceutical activities, where its statutory conditions are satisfied.

Criminal responsibility requires proof of the elements of the relevant offence. A regulatory violation does not automatically establish criminal guilt.

13. Intellectual property protection in stem-cell biotechnology

Stem-cell research also creates intellectual property questions.

Russian intellectual property protection is principally governed by Part IV of the Civil Code of the Russian Federation.

Important issues include:

Patent protection

Potentially patentable subject matter may include:

Novel cell-processing technologies.

Laboratory manufacturing techniques.

Novel culture methods.

Certain genetically engineered biological technologies.

Technical methods of producing cell-based products.

However, patentability is subject to statutory exclusions and requirements.

Commercial exploitation

Research institutions must consider:

Ownership of research results.

Employment-related inventions.

Technology-transfer agreements.

Licensing arrangements.

Research collaboration agreements.

Protection of confidential manufacturing processes.

A patent over a laboratory technique does not automatically authorize clinical application of the resulting cell product.

14. Major regulatory challenges in Russia

Regulatory challengeLegal concern
Unapproved stem-cell treatmentsPatient safety and authorization
Embryonic stem-cell researchEthical and legal protection
Donor consentBiological-material rights
Genetic modificationScientific and biosafety controls
Private stem-cell clinicsMedical and manufacturing licences
International collaborationCross-border data and material transfers
Personalized cell therapyIndividual authorization requirements
Long-term clinical risksPost-treatment safety monitoring
Commercial exploitationIntellectual property and consumer protection

15. Important international legal considerations

Russian stem-cell research can also involve international legal obligations.

Relevant instruments include:

The UNESCO Universal Declaration on the Human Genome and Human Rights, 1997.

The UNESCO Universal Declaration on Bioethics and Human Rights, 2005.

The Convention on Biological Diversity, 1992.

The Nagoya Protocol, 2010, where applicable to access to genetic resources and benefit-sharing.

These instruments provide international principles concerning human dignity, research ethics, biological resources and scientific cooperation.

Their domestic legal effect depends on Russia's treaty commitments, applicable implementation measures and the nature of the particular research activity.

16. Critical legal analysis

Russia's stem-cell regulatory system presents several important legal questions.

First, the classification problem: Determining whether a particular cell-based intervention constitutes a biomedical cell product, a transplant procedure, a medicinal product or scientific research can be legally complex.

Second, the innovation problem: Individualized cell therapies may develop faster than conventional product-registration procedures. The 2024 authorization framework addresses some of these difficulties.

Third, the ethical problem: Embryonic research, donor rights and genetic modification require careful consideration of human dignity and research ethics.

Fourth, the liability problem: Long-term complications may create difficulties in proving causation between a particular cell-based intervention and subsequent injury.

Fifth, the commercialization problem: Commercial stem-cell clinics must distinguish scientifically established treatment from experimental procedures and must not make unsupported therapeutic claims.

17. Conclusion

Stem-cell biotechnology in Russia is governed primarily by Federal Law No. 180-FZ of 23 June 2016, supplemented by Federal Law No. 323-FZ, licensing legislation, Ministry of Health regulations and government resolutions.

The 2024 individualized biomedical cell-product framework represents an important development in personalized regenerative medicine.

The Institute of Human Stem Cells v. Roszdravnadzor dispute, Case No. A40-58903/2016, provides useful historical judicial guidance concerning licensing and regulatory supervision of cellular medical technologies. However, it predates the implementation of the present biomedical cell-product framework.

The central legal objective is to balance scientific innovation with patient safety, donor protection, ethical research, manufacturing quality and regulatory accountability.

18. Important legal references for academic research

Legal instrumentSubject
Federal Law No. 180-FZ (2016)Biomedical cell products
Federal Law No. 323-FZ (2011)General healthcare regulation
Federal Law No. 99-FZ (2011)Licensing
Government Resolution No. 1184 (2018)Cell-product manufacturing licences
Ministry of Health Order No. 512n (2018)Good practice for handling cell products
Government Resolution No. 384 (2024)Individualized cell-product regulation
Government Resolution No. 385 (2024)Authorization for individualized products
Government Resolution No. 1062 (2021)State supervision

Primary legal research sources

Federal Law No. 180-FZ – Official legal text and amendments

Federal Law No. 180-FZ – GARANT legal database

Government Resolution No. 385 of 2024

Government Resolution No. 1184 of 2018

Supreme Court decision – Case No. A40-58903/2016

Roszdravnadzor – Biomedical cell-product regulation

Research note: The cited Supreme Court decision is a genuine related cellular-technology licensing dispute, not a direct precedent under Federal Law No. 180-FZ. The distinction is important when preparing a dissertation, research article or comparative biotechnology-law study.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT